TY - JOUR
T1 - Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage
T2 - Economic evaluation of a phase III clinical trial in Europe and Australia
AU - Glick, Henry
AU - Willke, Richard
AU - Polsky, Daniel
AU - Liana, Ted
AU - Alves, Wayne M.
AU - Kassell, Neal
AU - Schulman, Kevin
N1 - Funding Information:
The authors thank the economists in six countries who developed the unit costing data used in this analysis. Partial support for this research was provided by a grant from Pharmacia & Upjohn, Inc., Kalamazoo, Michigan.
PY - 1998
Y1 - 1998
N2 - This study used data from a multinational phase III randomized, double- blind, vehicle-controlled trial to evaluate the cost-effectiveness of tirilazad mesylate (Freedox®) in the treatment of aneurysmal subarachnoid hemorrhage. In men, therapy with 6 mg/kg per day of tirilazad mesylate was associated with significantly increased survival, increased cost of care, and ratios of cost per death averted that compare favorably with the ratios of other life and death interventions. In women, it appeared to have no effects on costs or survival. Further clinical studies may provide additional information about the cost-effectiveness of this intervention.
AB - This study used data from a multinational phase III randomized, double- blind, vehicle-controlled trial to evaluate the cost-effectiveness of tirilazad mesylate (Freedox®) in the treatment of aneurysmal subarachnoid hemorrhage. In men, therapy with 6 mg/kg per day of tirilazad mesylate was associated with significantly increased survival, increased cost of care, and ratios of cost per death averted that compare favorably with the ratios of other life and death interventions. In women, it appeared to have no effects on costs or survival. Further clinical studies may provide additional information about the cost-effectiveness of this intervention.
UR - http://www.scopus.com/inward/record.url?scp=0031911996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031911996&partnerID=8YFLogxK
U2 - 10.1017/S026646230001059X
DO - 10.1017/S026646230001059X
M3 - Review article
C2 - 9509802
AN - SCOPUS:0031911996
SN - 0266-4623
VL - 14
SP - 145
EP - 160
JO - International journal of technology assessment in health care
JF - International journal of technology assessment in health care
IS - 1
ER -